Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2016 10:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Appoints Kristen Hege, M.D., to Board of Directors

CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on...
June 16, 2016 07:30 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Series C Financing

$33 million raise expands top-tier investor syndicate and provides strong financial base for pipeline and platform development IND filing for lead product candidate XMT-1522 expected in...
April 18, 2016 09:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics’ New Immunoconjugate Demonstrates Anti-Cancer Activity in Non-Small Cell Lung Cancer and Ovarian Cancer Tumor Models

CAMBRIDGE, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that preclinical data for its new immunoconjugate product candidate, XMT-1536, demonstrated...
March 18, 2016 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Data on New Preclinical Product Candidate at the 2016 American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., March 18, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present two posters, one of which includes data on its new preclinical immunoconjugate,...
February 29, 2016 08:00 ET | Source: Mersana Therapeutics, Inc.

Dr. Michael J. Kaufman Joins Mersana Therapeutics as Senior Vice President of Chemistry, Manufacturing and Controls

CAMBRIDGE, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that Michael J. Kaufman, Ph.D., has been appointed Senior Vice President, Chemistry, Manufacturing and...
December 11, 2015 10:02 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics' Lead Immunoconjugate Continues to Demonstrate Complete Tumor Regressions in Multiple HER2-Expressing Breast Cancer Tumor Models

Data validate the potential of XMT-1522 to expand number of patients who may benefit from HER2-targeted therapies IND anticipated mid-2016 CAMBRIDGE, Mass., Dec. 11, 2015 (GLOBE NEWSWIRE) --...
November 30, 2015 16:30 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Poster at the 2015 San Antonio Breast Cancer Symposium

CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present a poster at the 2015 San Antonio Breast Cancer Symposium, taking place December...
October 15, 2015 16:30 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at World ADC San Diego

CAMBRIDGE, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced its presentation at World ADC San Diego, taking place October 19-22, 2015, at the Sheraton San Diego...
April 17, 2015 16:21 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics' Lead Fleximer(R) Immunoconjugate Demonstrates Potent Activity in Low HER2-Expressing Tumor Models

– XMT-1522 Designed to Expand Patient Population Treated With HER2-Targeted Therapy – – Complete Tumor Regressions Observed in HER2 1+ and 2+ Cancer Models Refractory to Current...
April 15, 2015 09:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Late-Breaking Poster at AACR Annual Meeting 2015

CAMBRIDGE, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present two posters, including a late-breaker with data from its lead immunoconjugate...